Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation

Detalles Bibliográficos
Autores principales: Heidel, F., Hochhaus, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288260/
https://www.ncbi.nlm.nih.gov/pubmed/32528040
http://dx.doi.org/10.1038/s41375-020-0898-6
_version_ 1783545237656829952
author Heidel, F.
Hochhaus, A.
author_facet Heidel, F.
Hochhaus, A.
author_sort Heidel, F.
collection PubMed
description
format Online
Article
Text
id pubmed-7288260
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72882602020-06-11 Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation Heidel, F. Hochhaus, A. Leukemia Editorial Nature Publishing Group UK 2020-06-11 2020 /pmc/articles/PMC7288260/ /pubmed/32528040 http://dx.doi.org/10.1038/s41375-020-0898-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Editorial
Heidel, F.
Hochhaus, A.
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
title Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
title_full Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
title_fullStr Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
title_full_unstemmed Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
title_short Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
title_sort holding covid in check through jak? the mpn-approved compound ruxolitinib as a potential strategy to treat sars-cov-2 induced systemic hyperinflammation
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288260/
https://www.ncbi.nlm.nih.gov/pubmed/32528040
http://dx.doi.org/10.1038/s41375-020-0898-6
work_keys_str_mv AT heidelf holdingcovidincheckthroughjakthempnapprovedcompoundruxolitinibasapotentialstrategytotreatsarscov2inducedsystemichyperinflammation
AT hochhausa holdingcovidincheckthroughjakthempnapprovedcompoundruxolitinibasapotentialstrategytotreatsarscov2inducedsystemichyperinflammation

Ejemplares similares